GEN Podcasts

The Sounds of Science podcast is brought to you by GEN. Listen as members of the editorial team—Editor-in-Chief John Sterling, Technical Editor Jeff Buguliskis, and Senior News Editor Alex Philippidis—showcase innovative research, new initiatives, and important policy by interviewing thought-leaders, eminent life-science researchers, and company leaders. These short, but informative podcasts will keep you up-to-date with the latest and most important life science advances.

Millipore is using its expertise in biomanufacturing to take advantage of the growing interest in continuous or next generation bioprocessing. The company is investing in specific technologies in terms of dedicated teams, focused R&D efforts, and product-development projects.

A research team from Vanderbilt University, University of North Carolina, and Gilead Sciences has just released new findings in Science Translational Medicine that a new antiviral drug candidate inhibits a broad range of coronaviruses, including SARS and MERS.

Team believes a rational therapeutic design approach will allow scientists to transform how the disease is tackled. Quantum dot technology also should be applicable to other autoimmune diseases as well.

Sara Radcliffe, President and CEO of the California Life Sciences Association, discusses where Scott Gottlieb, M.D., is most likely to impact biopharma, and what the industry hopes he will accomplish as the FDA’s new commissioner.

Mary Woolley, President of Research!America, which advocates for medical and health research funding, talks about how her group and other advocates plan to fight back against President Donald Trump’s one-two punch to NIH funding. Researchers will be key to those efforts, she says.

A recent study suggest that children with sensitive genotypes who come from low-income homes will be less financially successful than their same sex sibling without those genotypes. But children with those same genotypes from a high-income home would actually fare better economically as young adults than their brother or sister.

Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics’ halting development of JCAR015? How could some second-tier companies yet come out on top in the “car race”?

Scientists have long written off cannibalism as a strange phenomenon with little biological significance. However, the true nature of cannibalism—the role it plays in evolution as well as human history—is even more intriguing (and more normal) than the misconceptions we’ve come to accept as fact.

Nicole M. Nichols, Ph.D., group leader for DNA amplification development at New England Biolabs, discusses the third national Genes in Space competition. The winner will have his or her experiment carried out aboard the International Space Station.

Bill Warren, partner with the law firm Eversheds Sutherland and chair of its biotechnology and life sciences team, discusses the ruling by a three-judge panel of the Patent Trial and Appeal Board siding with the Broad Institute of MIT and Harvard in the bitter legal battle over who invented CRISPR (clustered regularly interspaced short palindromic repeats) gene-editing technology.

Jodie Morrison, CEO and President of Tokai Pharmaceuticals, is one of nearly 200 biopharma leaders who recently signed an open letter endorsing a Top Ten of best practices for advancing gender diversity, from the boardroom to the C-suite to the lab.